Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial

BACKGROUND: Clozapine causes significant metabolic disturbances including obesity and type 2 diabetes. Recent evidence that reduced glucagon-like-peptide-1 (GLP-1) may contribute to aetiology of clozapine-associated metabolic dysregulation suggests a potential therapeutic role for GLP-1 agonists. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayfield, Karla, Siskind, Dan, Winckel, Karl, Hollingworth, Samantha, Kisely, Steve, Russell, Anthony W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal College of Psychiatrists 2015
Materias:
Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998934/
https://www.ncbi.nlm.nih.gov/pubmed/27703725
http://dx.doi.org/10.1192/bjpo.bp.115.001073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998934/
https://www.ncbi.nlm.nih.gov/pubmed/27703725
http://dx.doi.org/10.1192/bjpo.bp.115.001073

Ejemplares similares